Sandoz, Mylan And Teva Take Bigger Steps To Tackle COVID-19
Sandoz Sponsors Hydroxychloroquine For Large Clinical Trial
Executive Summary
Sandoz is sponsoring a major hydroxychloroquine trial while other major industry players like Teva, Mylan, Apotex, Stada and Lupin are also accelerating efforts to fight the coronavirus crisis. Accord and Wavelength Pharma have stepped up their manufacturing to meet demand, as the AAM has cancelled its annual meeting.
You may also be interested in...
Wavelength Expands In India With Vanamali Deal
Israel-based API specialist Wavelength Pharmaceuticals has expanded its operations in India by acquiring a majority stake in starting materials and intermediates provider Vanamali Organics.
WHO Stops Clinical Trials Involving Hydroxychloroquine And HIV Drugs
The WHO’s “Solidarity” trial investigators have decided to interrupt the trials with immediate effect since the clinical trial found that hydroxychloroquine and lopinavir/ritonavir “produced little or no reduction in the mortality of the hospitalized COVID-19 patients.”
Teva, Sandoz And Accord Take COVID-19 Action
While Teva has helped to mitigate a Canadian shortage of salbutamol inhalers, Accord has struck a deal with the UK government to supply hydroxychloroquine. Sandoz is bolstering its inventory to meet demand and Apotex is donating critical medicines, while MedPharm’s new testing model will screen drugs for therapeutic effectiveness and Beximco is focusing on manufacturing hydroxychloroquine, favipiravir and ivermectin.